NCT04870424View on ClinicalTrials.gov

Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

PHASE3CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 21, 2021

Primary Completion Date

May 26, 2024

Study Completion Date

June 3, 2025

Conditions

Transcatheter Aortic Valve ReplacementAtrial Fibrillation New OnsetPacemakerColchicine

Interventions

DRUG

Colchicine

Colchicine in a loading dosage of 1mg single dose per os the day before TAVI and 1mg single dose at the day of procedure. Thereafter, colchicine 0.5mg once daily per os up to post-procedural day 12.

DRUG

Placebo

Placebo once daily per os the day before TAVI and once at the day of procedure. Thereafter, once daily per os up to post-procedural day 12.

Trial Locations (1)

3010

Inselspital, Bern University Hospital, Department of Cardiology, Bern

All Listed Sponsors

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT04870424 - Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement | Biotech Hunter | Biotech Hunter